Otsuka Holdings reports strong nine-month growth, raises full-year outlook

Otsuka Holdings reported consolidated revenue of 1,818,743 million yen for the nine-month period ended September 30, 2025, a 5.1% increase year-over-year. Business profit rose 1.3% to 366,503 million yen, while operating profit surged 56.1% to 407,421 million yen. Profit attributable to owners of the company increased by 55.3% to 297,658 million yen, with basic earnings per share at 560.81 yen. The strong performance was primarily attributed to robust sales of antipsychotic agents REXULTI/RXULTI and anti-cancer agent LONSURF.

Total assets increased to 3,959,538 million yen, with current assets at 1,508,888 million yen and non-current assets at 2,450,650 million yen. The company also announced strategic acquisitions, including Araris Biotech AG and Otsuka ICU Medical LLC, which impacted goodwill and other non-current assets. In light of these results, Otsuka Holdings revised its full-year revenue forecast to 2,420,000 million yen and its business profit forecast to 410,000 million yen for the fiscal year ending December 31, 2025.

The annual dividend forecast for FY2025 is 140.00 yen per share, with a second-quarter dividend of 70.00 yen and a year-end dividend of 70.00 yen. Research and development expenses for the nine-month period totaled 248,648 million yen, supporting the development pipeline of key pharmaceutical products.